Free UK delivery when spending £50+ on one time purchases. IMPORTANT: Non UK orders – Custom charges may apply.

SlimBiome® reduces hunger and food cravings in healthy overweight and obese adults

Lightowler H

Kolida S

Wood C

Achebe I

Brennan H

Ahlstrom LC


SlimBiome is a patented formulation designed to promote the feeling of fullness, burn calories by promoting a healthy metabolism and to maintain blood sugar levels. SlimBiome® reduces food cravings and as such helps reduce body weight and aids the sustainability of weight loss


To investigate the impact of SlimBiome® on satiation (fullness), satiety (hunger and cravings between meals), and food intake/choice in 20, otherwise healthy, overweight to obese women over a 4-week period


Parallel, double blind, placebo, controlled randomised design:

  • 20 females (18­‐65 years), BMI 25-­35kg/m2
  • Randomly assigned to SlimBiome® or placebo treatment
  • Take SlimBiome®/ placebo with 200ml water, three times daily 30min before each main meal for 4 weeks, while following the Eat Well Guidelines for healthy eating (Public Health England)


Visual analogue scale (VAS) measurements on feeling of
fullness before (left) and after (right) product consumption on visit days
show marked increases in the SlimBiome® group but not the
placebo. Effect is enhanced after SlimBiome intake

Fat intake during ad libitum breakfast decreases in the SlimBiome® group but increases in the placebo between weeks 0 and 4

VAS responses for food cravings, difficulty to resist food
cravings in general, and in particular cravings for sweet foods, show
marked decreases in the SlimBiome® group but not the placebo


SlimBiome ingestion may help control overeating by:
• Increasing the feeling of fullness
• Decreasing food cravings
• Decreasing cravings for sweet foods
• Reducing fat intake

SlimBiome® may be used as an effective means of supporting hunger-­free weight management when combined with healthy eating

Conflict of interest
The authors declare no conflict of interest. This human intervention study was funded by OptiBiotix health PLC and carried out independently by Oxford Brookes University